EFG Asset Management North America Corp. Acquires 27,192 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

EFG Asset Management North America Corp. boosted its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 59.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 73,160 shares of the company’s stock after purchasing an additional 27,192 shares during the period. EFG Asset Management North America Corp. owned approximately 0.12% of Vera Therapeutics worth $3,092,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. increased its holdings in shares of Vera Therapeutics by 14.3% in the fourth quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company’s stock worth $124,737,000 after buying an additional 369,387 shares during the period. Jennison Associates LLC grew its position in Vera Therapeutics by 82.0% during the 4th quarter. Jennison Associates LLC now owns 813,861 shares of the company’s stock worth $34,418,000 after acquiring an additional 366,763 shares during the last quarter. Victory Capital Management Inc. increased its stake in Vera Therapeutics by 515.0% in the 4th quarter. Victory Capital Management Inc. now owns 235,267 shares of the company’s stock worth $9,949,000 after purchasing an additional 197,014 shares during the period. Holocene Advisors LP lifted its position in Vera Therapeutics by 8.8% in the third quarter. Holocene Advisors LP now owns 1,954,528 shares of the company’s stock valued at $86,390,000 after purchasing an additional 158,451 shares during the last quarter. Finally, Lord Abbett & CO. LLC boosted its stake in shares of Vera Therapeutics by 41.1% during the third quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company’s stock valued at $18,830,000 after purchasing an additional 124,197 shares during the period. 99.21% of the stock is owned by institutional investors.

Vera Therapeutics Stock Performance

Vera Therapeutics stock opened at $27.15 on Tuesday. Vera Therapeutics, Inc. has a fifty-two week low of $25.99 and a fifty-two week high of $51.61. The stock’s 50 day simple moving average is $31.50 and its two-hundred day simple moving average is $39.20. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The stock has a market cap of $1.73 billion, a price-to-earnings ratio of -10.40 and a beta of 1.17.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.11. As a group, analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Insider Transactions at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 17,500 shares of the business’s stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $41.74, for a total transaction of $730,450.00. Following the sale, the chief executive officer now owns 143,603 shares of the company’s stock, valued at $5,993,989.22. The trade was a 10.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 21.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Wolfe Research initiated coverage on shares of Vera Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 target price on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 4th. The Goldman Sachs Group assumed coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $58.00 target price for the company. Finally, Guggenheim boosted their price target on Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $64.67.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.